BCS II waiver approach [Dissolution / BCS / IVIVC]

posted by yuvaneshwari – India, 2019-01-23 07:09 (2208 d 01:04 ago) – Posting: # 19801
Views: 4,122

Dear All,

Drug compound is BCS-II [dosage form is solution filled in capsule], and objective is to formulate with Q1 & Q2 sameness to that of Reference. Since API is in solution state filled in capsule, its solubility/bioavailability is improved tremendously.

In the above scenario, can we consider for BCS based waiver approach ?

Complete thread:

UA Flag
Activity
 Admin contact
23,376 posts in 4,912 threads, 1,667 registered users;
151 visitors (0 registered, 151 guests [including 13 identified bots]).
Forum time: 08:13 CET (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5